Parkinsonism, movement disorders and genetics in frontotemporal dementia

Nature Reviews Neurology

Volumn 12, Issue 3, 2016, Pages 175-185

  Baizabal Carvallo, José Fidel ^a   Jankovic, Joseph ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOSOME PROTEIN; PROGRANULIN; PROTEIN CHMP2B; RNA BINDING PROTEIN; TAR DNA BINDING PROTEIN; TAU PROTEIN; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2; UNCLASSIFIED DRUG; VALOSIN CONTAINING PROTEIN;

AUTOPSY; C9ORF72 GENE; CHOREA; CHROMOSOME 17; CHROMOSOME 9; CORTICOBASAL SYNDROME; DISEASE ASSOCIATION; DYSTONIA; FRONTOTEMPORAL DEMENTIA; GENE; GENETIC CODE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MISSENSE MUTATION; MOLECULAR GENETICS; MOTOR DYSFUNCTION; MOTOR NEURON DISEASE; MUTATIONAL ANALYSIS; MYOCLONUS; NEUROLOGIC DISEASE; OROFACIAL DYSKINESIA; PARKINSONISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RICHARDSON SYNDROME; SHY DRAGER SYNDROME; ANIMAL; ATROPHY; BRAIN; GENETICS; MOVEMENT DISORDERS; PARKINSONIAN DISORDERS; PATHOLOGY;

ANIMALS; ATROPHY; BRAIN; FRONTOTEMPORAL DEMENTIA; HUMANS; MOVEMENT DISORDERS; PARKINSONIAN DISORDERS;

EID: 84959337230     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2016.14     Document Type: Review

References (157)

1. Mercy L., Hodges J. R., Dawson K., Barker R. A., & Brayne C. Incidence of early-onset dementias in Cambridgeshire, United Kingdom. Neurology 71, 1496-1499 (2008
2. Perry D. C., & Miller B. L. Frontotemporal dementia. Semin. Neurol. 33, 336-341 (2013
3. Seltman R. E., & Matthews B. R. Frontotemporal lobar degeneration: epidemiology, pathology, diagnosis and management. CNS Drugs 26, 841-870 (2012
4. Teichmann M., et al. Deciphering logopenic primary progressive aphasia: a clinical, imaging and biomarker investigation. Brain 136, 3474-3488 (2013
5. Fujioka S., & Wszolek Z. K. Clinical aspects of familial forms of frontotemporal dementia associated with parkinsonism. J. Mol. Neurosci. 45, 359-365 (2011
6. Siuda J., Fujioka S., & Wszolek Z. K. Parkinsonian syndrome in familial frontotemporal dementia. Parkinsonism Relat. Disord. 20, 957-964 (2014
7. Neary D., et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 51, 1546-1554 (1998
8. Rascovsky K., et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134, 2456-2477 (2011
9. The Lund and Manchester groups. Clinical and neuropathological criteria for frontotemporal dementia. J. Neurol. Neurosurg. Psychiatry 57, 416-418 (1994
10. Diehl-Schmid J., et al. Extrapyramidal signs, primitive reflexes and incontinence in fronto-temporal dementia. Eur. J. Neurol. 14, 860-864 (2007
11. Padovani A., Agosti C., Premi E., Bellelli G., & Borroni B. Extrapyramidal symptoms in frontotemporal dementia: prevalence and clinical correlations. Neurosci. Lett. 422, 39-42 (2007
12. Ling H., et al. Does corticobasal degeneration exist? A clinicopathological re evaluation. Brain 133, 2045-2057 (2010
13. Stamelou M., Quinn N. P., & Bhatia K. P. 'Atypical' atypical parkinsonism: new genetic conditions presenting with features of progressive supranuclear palsy, corticobasal degeneration, or multiple system atrophy - a diagnostic guide. Mov. Disord. 28, 1184-1199 (2013
14. Respondek G., et al. The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov. Disord. 29, 1758-1766 (2014
15. Armstrong M. J., et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 80, 496-503 (2013
16. Mathew R., Bak T. H., & Hodges J. R. Diagnostic criteria for corticobasal syndrome: a comparative study. J. Neurol. Neurosurg. Psychiatry 83, 405-410 (2012
17. Dickson D. W., Ahmed Z., Algom A. A., Tsuboi Y., & Josephs K. A. Neuropathology of variants of progressive supranuclear palsy. Curr. Opin. Neurol. 23, 394-400 (2010
18. Williams D. R., et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain 128, 1247-1258 (2005
19. Foster N. L., et al. Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. Ann. Neurol. 41, 706-715 (1997
20. Hutton M., et al. Association of missense and 5 splice-site mutations in tau with the inherited dementia FTDP 17. Nature 393, 702-705 (1998
21. Baker M., et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442, 916-919 (2006
22. Ludolph A. C., et al. Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur. J. Neurol. 16, 297-309 (2009
23. Yu C. E., et al. The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration. Arch. Neurol. 67, 161-170 (2010
24. van Swieten J. C., & Heutink P. Mutations in progranulin (GRN) within the spectrum of clinical and pathological phenotypes of frontotemporal dementia. Lancet Neurol. 7, 965-974 (2008
25. Boeve B. F., & Hutton M. Refining frontotemporal dementia with parkinsonism linked to chromosome 17: introducing FTDP 17 (MAPT) and FTDP 17 (PGRN). Arch. Neurol. 65, 460-464 (2008
26. Rohrer J. D., et al. The heritability and genetics of frontotemporal lobar degeneration. Neurology 73, 1451-1456 (2009
27. Arima K., et al. Two brothers with frontotemporal dementia and parkinsonism with an N279K mutation of the tau gene. Neurology 54, 1787-1795 (2000
28. Yasuda M., et al. A mutation in the microtubule-associated protein tau in pallido-nigro-luysian degeneration. Neurology 53, 864-868 (1999
29. Pickering-Brown S. M., et al. Inherited frontotemporal dementia in nine British families associated with intronic mutations in the tau gene. Brain 125, 732-751 (2002
30. Bermingham N., Cowie T. F., Paine M., Storey E., & McLean C. Frontotemporal dementia and parkinsonism linked to chromosome 17 in a young Australian patient with the G389R Tau mutation. Neuropathol. Appl. Neurobiol. 34, 366-370 (2008
31. Rossi G., et al. The G389R mutation in the MAPT gene presenting as sporadic corticobasal syndrome. Mov. Disord. 23, 892-895 (2008
32. Tacik P., et al. A novel tau mutation in exon 12, p.Q336H, causes hereditary pick disease. J. Neuropathol. Exp. Neurol. 74, 1042-1052 (2015
33. Tacik P., et al. A novel tau mutation p.K317N, causes globular glial tauopathy. Acta Neuropathol. 130, 199-214 (2015
34. Chaunu M. P., et al. Juvenile frontotemporal dementia with parkinsonism associated with tau mutation G389R. J. Alzheimers Dis. 37, 769-776 (2013
35. Lossos A., et al. Frontotemporal dementia and parkinsonism with the P301S tau gene mutation in a Jewish family. J. Neurol. 250, 733-740 (2003
36. Sperfeld A. D., et al. FTDP 17: an early phenotype with parkinsonism and epileptic seizures caused by a novel mutation. Ann. Neurol. 46, 708-715 (1999
37. Werber E., Klein C., Grünfeld J., & Rabey J. M. Phenotypic presentation of frontotemporal dementia with parkinsonism-chromosome 17 type P301S in a patient of Jewish-Algerian origin. Mov. Disord. 18, 595-598 (2003
38. Boeve B. F., et al. Longitudinal characterization of two siblings with frontotemporal dementia and parkinsonism linked to chromosome 17 associated with the S305N tau mutation. Brain 128, 752-772 (2005
39. Skoglund L., et al. The tau S305S mutation causes frontotemporal dementia with parkinsonism. Eur. J. Neurol. 15, 156-161 (2008
40. Lynch T., et al. Clinical characteristics of a family with chromosome 17 linked disinhibition-dementia- parkinsonism-amyotrophy complex. Neurology 44, 1878-1884 (1994
41. Rohrer J. D., et al. Novel L284R MAPT mutation in a family with an autosomal dominant progressive supranuclear palsy syndrome. Neurodegener. Dis. 8, 149-152 (2011
42. Ogaki K., et al. Analyses of the MAPT, PGRN, and C9orf72 mutations in Japanese patients with FTLD, PSP, and CBS. Parkinsonism Relat. Disord. 19, 15-20 (2013
43. Spina S., et al. The tauopathy associated with mutation +3 in intron 10 of tau: characterization of the MSTD family. Brain 131, 72-89 (2008
44. Baba Y., et al. Clinical and genetic features of families with frontotemporal dementia and parkinsonism linked to chromosome 17 with a P301S tau mutation. J. Neural Transm. (Vienna) 114, 947-950 (2007
45. Kouri N., et al. Novel mutation in MAPT exon 13 (p.N410H) causes corticobasal degeneration. Acta Neuropathol. 127, 271-282 (2014
46. Kelly B. J., et al. Prominent phenotypic variability associated with mutations in progranulin. Neurobiol. Aging 30, 739-751 (2009
47. Le Ber I., et al. Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study. Brain 131, 732-746 (2008
48. Davion S., et al. Clinicopathologic correlation in PGRN mutations. Neurology 69, 1113-1121 (2007
49. Masellis M., et al. Novel splicing mutation in the progranulin gene causing familial corticobasal syndrome. Brain 129, 3115-3123 (2006
50. Josephs K. A., et al. Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions with progranulin gene (PGRN) mutations. J. Neuropathol. Exp. Neurol. 66, 142-151 (2007
51. Spina S., et al. Corticobasal syndrome associated with the A9D progranulin mutation. J. Neuropathol. Exp. Neurol. 66, 892-900 (2007
52. Benussi L., et al. A novel deletion in progranulin gene is associated with FTDP 17 and CBS. Neurobiol. Aging 29, 427-435 (2008
53. Benussi L., et al. Progranulin Leu271LeufsX10 is one of the most common FTLD and CBS associated mutations worldwide. Neurobiol. Dis. 33, 379-385 (2009
54. Rusina R., et al. FTLD-TDP with motor neuron disease, visuospatial impairment and a progressive supranuclear palsy-like syndrome: broadening the clinical phenotype of TDP 43 proteinopathies. A report of three cases. BMC Neurol. 11, 50 (2011
55. Renton A. E., et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21 linked ALS-FTD. Neuron 72, 257-268 (2011
56. Khan B. K., et al. Atypical, slowly progressive behavioural variant frontotemporal dementia associated with C9ORF72 hexanucleotide expansion. J. Neurol. Neurosurg. Psychiatry 83, 358-364 (2012
57. Van Langenhove T., et al. Distinct clinical characteristics of C9orf72 expansion carriers compared with GRN, MAPT, and nonmutation carriers in a Flanders-Belgian FTLD cohort. JAMA Neurol. 70, 365-373 (2013
58. Boeve B. F., et al. Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain 135, 765-783 (2012
59. O'Dowd S., et al. C9ORF72 expansion in amyotrophic lateral sclerosis/frontotemporal dementia also causes parkinsonism. Mov. Disord. 27, 1072-1074 (2012
60. Goldman J. S., et al. Multiple system atrophy and amyotrophic lateral sclerosis in a family with hexanucleotide repeat expansions in C9orf72. JAMA Neurol. 71, 771-774 (2014
61. Cooper-Knock J., et al. C9ORF72 expansions, parkinsonism, and Parkinson disease: a clinicopathologic study. Neurology 81, 808-811 (2013
62. Lindquist S. G., et al. Corticobasal and ataxia syndromes widen the spectrum of C9ORF72 hexanucleotide expansion disease. Clin. Genet. 83, 279-283 (2013
63. Snowden J. S., et al. Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. Brain 135, 693-708 (2012
64. Daoud H., et al. Investigation of C9orf72 repeat expansions in Parkinson's disease. Neurobiol. Aging 34, 1710.e7-1710.e9 (2013
65. Harms M. B., et al. Parkinson disease is not associated with C9ORF72 repeat expansions. Neurobiol. Aging 34, 1519.e1-1519.e2 (2013
66. Xi Z., et al. Investigation of c9orf72 in 4 neurodegenerative disorders. Arch. Neurol. 69, 1583-1590 (2012
67. Lesage S., et al. C9orf72 repeat expansions are a rare genetic cause of parkinsonism. Brain 136, 385-391 (2013
68. Majounie E., et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 11, 323-330 (2012
69. Nuytemans K., et al. C9ORF72 intermediate repeat copies are a significant risk factor for Parkinson disease. Ann. Hum. Genet. 77, 351-363 (2013
70. Akimoto C., et al. No GGGGCC-hexanucleotide repeat expansion in C9ORF72 in parkinsonism patients in Sweden. Amyotroph. Lateral Scler. Frontotemporal Degener. 14, 26-29 (2013
71. Cooper-Knock J., Shaw P. J., & Kirby J. The widening spectrum of C9ORF72-related disease; genotype/phenotype correlations and potential modifiers of clinical phenotype. Acta Neuropathol. 127, 333-345 (2014
72. Dombroski B. A., et al. C9orf72 hexanucleotide repeat expansion and Guam amyotrophic lateral sclerosis-parkinsonism-dementia complex. JAMA Neurol. 70, 742-745 (2013
73. Floris G., et al. Frontotemporal dementia with psychosis, parkinsonism, visuo-spatial dysfunction, upper motor neuron involvement associated to expansion of C9ORF72: a peculiar phenotype? J. Neurol. 259, 1749-1751 (2012
74. Snowden J. S., et al. Psychosis, C9ORF72 and dementia with Lewy bodies. J. Neurol. Neurosurg. Psychiatry 83, 1031-1032 (2012
75. Robinson A., Davidson Y., Snowden J. S., & Mann D. M. C9ORF72 in dementia with Lewy bodies. J. Neurol. Neurosurg. Psychiatry 85, 1435-1436 (2014
76. Morgan S., et al. Differentiation of frontotemporal dementia from dementia with Lewy bodies using FP CIT SPECT. J. Neurol. Neurosurg. Psychiatry 83, 1063-1070 (2012
77. Johnson J. O., et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron 68, 857-864 (2010
78. Spina S., et al. Phenotypic variability in three families with valosin-containing protein mutation. Eur. J. Neurol. 20, 251-258 (2013
79. Majounie E., et al. Mutational analysis of the VCP gene in Parkinson's disease. Neurobiol. Aging 33, 209.e1-209.e2 (2012
80. Gydesen S., et al. Chromosome 3 linked frontotemporal dementia (FTD 3). Neurology 59, 1585-1594 (2002
81. Deng H., Gao K., & Jankovic J. The role of FUS gene variants in neurodegenerative diseases. Nat. Rev. Neurol. 10, 337-348 (2014
82. Isaacs A. M., Johannsen P., Holm I., & Nielsen J. E., & FReJA consortium. Frontotemporal dementia caused by CHMP2B mutations. Curr. Alzheimer Res. 8, 246-251 (2011
83. Yan J., et al. Frameshift and novel mutations in FUS in familial amyotrophic lateral sclerosis and ALS/dementia. Neurology 75, 807-814 (2010
84. Seelaar H., et al. Frequency of ubiquitin and FUS-positive, TDP 43 negative frontotemporal lobar degeneration. J. Neurol. 257, 747-753 (2010
85. Josephs K. A., et al. Caudate atrophy on MRI is a characteristic feature of FTLD-FUS. Eur. J. Neurol. 17, 969-975 (2010
86. Mosca L., et al. Wide phenotypic spectrum of the TARDBP gene: homozygosity of A382T mutation in a patient presenting with amyotrophic lateral sclerosis, Parkinson's disease, and frontotemporal lobar degeneration, and in neurologically healthy subject. Neurobiol. Aging 33, 1846.e1-1846.e4 (2012
87. Quadri M., et al. Broadening the phenotype of TARDBP mutations: the TARDBP Ala382Thr mutation and Parkinson's disease in Sardinia. Neurogenetics 12, 203-209 (2011
88. Rayaprolu S., et al. TARDBP mutations in Parkinson's disease. Parkinsonism Relat. Disord. 19, 312-315 (2013
89. Fujita Y., Ikeda M., Yanagisawa T., Senoo Y., & Okamoto K. Different clinical and neuropathologic phenotypes of familial ALS with A315E TARDBP mutation. Neurology 77, 1427-1431 (2011
90. Borghero G., et al. A patient carrying a homozygous p.A382T TARDBP missense mutation shows a syndrome including ALS, extrapyramidal symptoms, and FTD. Neurobiol. Aging 32, 2327.e1-2327.e5 (2011
91. Espay A. J., et al. Rapidly progressive atypical parkinsonism associated with frontotemporal lobar degeneration and motor neuron disease. J. Neurol. Neurosurg. Psychiatry 82, 751-753 (2011
92. Kabashi E., et al. No TARDBP mutations in a French Canadian population of patients with Parkinson disease. Arch. Neurol. 66, 281-282 (2009
93. Ticozzi N., et al. Mutational analysis of TARDBP in neurodegenerative diseases. Neurobiol. Aging 32, 2096-2099 (2011
94. Takahashi K., Rochford C. D., & Neumann H. Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells 2. J. Exp. Med. 201, 647-657 (2005
95. Bianchin M. M., et al. Nasu-Hakola disease (polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy - PLOSL): a dementia associated with bone cystic lesions. From clinical to genetic and molecular aspects. Cell. Mol. Neurobiol. 24, 1-24 (2004
96. Giraldo M., et al. Variants in triggering receptor expressed on myeloid cells 2 are associated with both behavioral variant frontotemporal lobar degeneration and Alzheimer's disease. Neurobiol. Aging 34, 2077.e11-2077.e18 (2013
97. Guerreiro R., et al. TREM2 variants in Alzheimer's disease. N. Engl. J. Med. 368, 117-127 (2013
98. Le Ber I., et al. Homozygous TREM2 mutation in a family with atypical frontotemporal dementia. Neurobiol. Aging 35, 2419.e23-2419.e25 (2014
99. Guerreiro R. J., et al. Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. JAMA Neurol. 70, 78-84 (2013
100. Rayaprolu S., et al. TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease. Mol. Neurodegener. 8, 19 (2013
101. Cairns N. J., et al. α internexin is present in the pathological inclusions of neuronal intermediate filament inclusion disease. Am. J. Pathol. 164, 2153-2161 (2004
102. Cairns N. J., et al. Clinical and neuropathologic variation in neuronal intermediate filament inclusion disease. Neurology 63, 1376-1384 (2004
103. Molina-Porcel L., et al. Clinical and pathological heterogeneity of neuronal intermediate filament inclusion disease. Arch. Neurol. 65, 272-275 (2008
104. Wong T. H., et al. PRKAR1B mutation associated with a new neurodegenerative disorder with unique pathology. Brain 137, 1361-1373 (2014
105. Mendez M. F., & Shapira J. S. The spectrum of recurrent thoughts and behaviors in frontotemporal dementia. CNS Spectr. 13, 202-208 (2008
106. Shigenobu K., et al. The Stereotypy Rating Inventory for frontotemporal lobar degeneration. Psychiatry Res. 110, 175-187 (2002
107. Mateen F. J., & Josephs K. A. The clinical spectrum of stereotypies in frontotemporal lobar degeneration. Mov. Disord. 24, 1237-1240 (2009
108. Jankovic J. in Principles and Practice of Movement Disorders 2nd edn Ch. 17 (eds Fahn S., Jankovic J., & Hallett M.) 380-388 (Churchill Linvingstone, 2011
109. Edwards M. J., Lang A. E., & Bhatia K. P. Stereotypies: a critical appraisal and suggestion of a clinically useful definition. Mov. Disord. 27, 179-185 (2012
110. Ames D., Cummings J. L., Wirshing W. C., Quinn B., & Mahler M. Repetitive and compulsive behavior in frontal lobe degenerations. J. Neuropsychiatry Clin. Neurosci. 6, 100-113 (1994
111. Prioni S., et al. Stereotypic behaviors in degenerative dementias. J. Neurol. 259, 2452-2459 (2012
112. Miller B. L., et al. A study of the Lund-Manchester research criteria for frontotemporal dementia: clinical and single-photon emission CT correlations. Neurology 48, 937-942 (1997
113. Bozeat S., Gregory C. A., Ralph M. A., & Hodges J. R. Which neuropsychiatric and behavioural features distinguish frontal and temporal variants of frontotemporal dementia from Alzheimer's disease? J. Neurol. Neurosurg. Psychiatry 69, 178-186 (2000
114. Nyatsanza S., et al. A study of stereotypic behaviours in Alzheimer's disease and frontal and temporal variant frontotemporal dementia. J. Neurol. Neurosurg. Psychiatry 74, 1398-1402 (2003
115. Snowden J. S., et al. Distinct behavioural profiles in frontotemporal dementia and semantic dementia. J. Neurol. Neurosurg. Psychiatry 70, 323-332 (2001
116. Ikeda M., et al. Efficacy of fluvoxamine as a treatment for behavioral symptoms in frontotemporal lobar degeneration patients. Dement. Geriatr. Cogn. Disord. 17, 117-121 (2004
117. Ondo W. G. Tetrabenazine treatment for stereotypies and tics associated with dementia. J. Neuropsychiatry Clin. Neurosci. 24, 208-214 (2012
118. Jankovic J., & Clarence-Smith K. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev. Neurother. 11, 1509-1523 (2011
119. Nielsen T. R., Bruhn P., Nielsen J. E., & Hjermind L. E. Behavioral variant of frontotemporal dementia mimicking Huntington's disease. Int. Psychogeriatr. 22, 674-677 (2010
120. Kovacs G. G., et al. TARDBP variation associated with frontotemporal dementia, supranuclear gaze palsy, and chorea. Mov. Disord. 24, 1843-1847 (2009
121. Wider C., et al. Progranulin gene mutation with an unusual clinical and neuropathologic presentation. Mov. Disord. 23, 1168-1173 (2008
122. Hensman Moss D. J., et al. C9orf72 expansions are the most common genetic cause of Huntington disease phenocopies. Neurology 82, 292-299 (2014
123. Dejesus-Hernandez M., et al. Analysis of the C9orf72 repeat in Parkinson's disease, essential tremor and restless legs syndrome. Parkinsonism Relat. Disord. 19, 198-201 (2013
124. Caviness J. N. Myoclonus and neurodegenerative disease - what's in a name? Parkinsonism Relat. Disord. 9, 185-192 (2003
125. Curcio S. A., et al. A large Calabrian kindred segregating frontotemporal dementia. J. Neurol. 249, 911-922 (2002
126. Bruni A. C., et al. Heterogeneity within a large kindred with frontotemporal dementia: a novel progranulin mutation. Neurology 69, 140-147 (2007
127. Pail M., Matej R., Husarova I., & Rektorova I. Generalized myoclonus as a prominent symptom in a patient with FTLD-TDP. J. Neurol. 260, 1681-1683 (2013
128. Vanek Z., & Jankovic J. Dystonia in corticobasal degeneration. Mov. Disord. 16, 252-257 (2001
129. Stamelou M., Alonso-Canovas A., & Bhatia K. P. Dystonia in corticobasal degeneration: a review of the literature on 404 pathologically proven cases. Mov. Disord. 27, 696-702 (2012
130. Merner N. D., et al. Exome sequencing identifies FUS mutations as a cause of essential tremor. Am. J. Hum. Genet. 91, 313-319 (2012
131. Deng H., Liang H., & Jankovic J. F box only protein 7 gene in parkinsonian-pyramidal disease. JAMA Neurol. 70, 20-24 (2013
132. Hopfner F., et al. The impact of rare variants in FUS in essential tremor. Mov. Disord. 30, 721-724 (2015
133. Ishii K., et al. Cerebral glucose metabolism in patients with frontotemporal dementia. J. Nucl. Med. 39, 1875-1878 (1998
134. Jeong Y., et al. 18F-FDG PET findings in frontotemporal dementia: an SPM analysis of 29 patients. J. Nucl. Med. 46, 233-239 (2005
135. Diehl-Schmid J., et al. Decline of cerebral glucose metabolism in frontotemporal dementia: a longitudinal 18F-FDG-PET-study. Neurobiol. Aging 28, 42-50 (2007
136. Garibotto V., et al. Subcortical and deep cortical atrophy in frontotemporal lobar degeneration. Neurobiol. Aging 32, 875-884 (2011
137. Looi J. C., et al. Caudate nucleus volumes in frontotemporal lobar degeneration: differential atrophy in subtypes. AJNR Am. J. Neuroradiol. 29, 1537-1543 (2008
138. Looi J. C., et al. Putaminal volume in frontotemporal lobar degeneration and Alzheimer disease: differential volumes in dementia subtypes and controls. AJNR Am. J. Neuroradiol. 30, 1552-1560 (2009
139. Halabi C., et al. Patterns of striatal degeneration in frontotemporal dementia. Alzheimer Dis. Assoc. Disord. 27, 74-83 (2013
140. Rinne J. O., et al. Striatal dopamine transporter and extrapyramidal symptoms in frontotemporal dementia. Neurology 58, 1489-1493 (2002
141. Sedaghat F., et al. Evaluation of dopaminergic function in frontotemporal dementia using I FP CIT single photon emission computed tomography. Neurodegener. Dis. 4, 382-385 (2007
142. Carecchio M., et al. Evidence of pre-synaptic dopaminergic deficit in a patient with a novel progranulin mutation presenting with atypical parkinsonism. J. Alzheimers Dis. 38, 747-752 (2014
143. Ittner L. M., et al. Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia. Proc. Natl Acad. Sci. USA 105, 15997-16002 (2008
144. Pal P. K., et al. Positron emission tomography in pallido-ponto-nigral degeneration (PPND) family (frontotemporal dementia with parkinsonism linked to chromosome 17 and point mutation in tau gene). Parkinsonism Relat. Disord. 7, 81-88 (2001
145. Selemon L. D., & Goldman-Rakic P. S. Longitudinal topography and interdigitation of corticostriatal projections in the rhesus monkey. J. Neurosci. 5, 776-794 (1985
146. Kobayashi K., et al. KP1 expression of ghost Pick bodies, amyloid P positive astrocytes and selective nigral degeneration in early onset Picks disease. Clin. Neuropathol. 18, 240-249 (1999
147. Woolley J. D., et al. Binge eating is associated with right orbitofrontal-insular-striatal atrophy in frontotemporal dementia. Neurology 69, 1424-1433 (2007
148. Josephs K. A., Whitwell J. L., & Jack C. R. Jr. Anatomic correlates of stereotypies in frontotemporal lobar degeneration. Neurobiol. Aging. 29, 1859-1863 (2008
149. Diehl-Schmid J., Onur O. A., Kuhn J., Gruppe T., & Drzezga A. Imaging frontotemporal lobar degeneration. Curr. Neurol. Neurosci. Rep. 14, 489 (2014
150. Gómez-Tortosa E., et al. Plasma progranulin levels in cortical dementia phenotypes with asymmetric perisylvian atrophy. Eur. J. Neurol. 20, 1319-1324 (2013
151. Finch N., et al. Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain 132, 583-591 (2009
152. Le Ber I. Genetics of frontotemporal lobar degeneration: an up date and diagnosis algorithm. Rev. Neurol. (Paris) 169, 811-819 (2013
153. Rostgaard N., Waldemar G., Nielsen J. E., & Simonsen A. H. Cerebrospinal fluid biomarkers in familial forms of Alzheimer's disease and frontotemporal dementia. Dement. Geriatr. Cogn. Disord. 40, 54-62 (2015
154. Fekete R., et al. Exome sequencing in familial corticobasal degeneration. Parkinsonism Relat. Disord. 19, 1049-1052 (2013
155. Dani M. Edison P., & Brooks D. J. Imaging biomarkers in tauopathies. Parkinsonism Relat. Disord. 22, S26-S28 (2016
156. Zhang J. Mapping neuroinflammation in frontotemporal dementia with molecular PET imaging. J. Neuroinflamm. 12, 108 (2015
157. Bang J., Spina S., & Miller B. L. Frontotemporal dementia. Lancet 386, 1672-1682 (2015